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Abstract
Fibrogenesis is a common feature of many diseases where there is severe insult to the liver. The hepatic stellate
cell trans-differentiation into a myofibroblast has been identified as an important event in liver fibrogenesis and
has been well investigated over the last few years in a number of liver diseases. The trans-differentiation process
can be monitored in vitro by evaluation of biomarkers that are characteristic of normal quiescent hepatic stellate
cells or activated myofibroblasts. Two major parasitic diseases associated with liver injury and fibrosis are schistoso-
miasis and echinococcosis. Recent studies have highlighted a role for activated hepatic stellate cells in both murine
and human schistosomiasis as well as demonstrating that schistosome antigens are able to regulate this trans-dif-
ferentiation process. Study of the hepatic stellate cell and its interaction with parasite-derived antigens may be
pivotal in our understanding of the pathology associated with schistosomiasis and other parasitic diseases, includ-
ing echinococcosis, as well as revealing new information on the trans-differentiation process in this cell type.
Introduction
Fibrosis is a pathological process arising from abnormal
and continuous wound repair processes and is a well
recognised feature of several important parasitic infec-
tions. Hydatid cysts, arising from infection with meta-
cestodes of Echinococcus granulosus or E. multilocularis,
and eggs released from Schistosoma mansoni and
S. japonicum localise primarily in the liver where it is
thought that host immune responses direct fibrogenesis.
The resultant fibrosis of the liver may be associated
with severe host pathology in schistosomiasis [1], or in
echinococcosis with a peri-parasitic extracellular matrix
(ECM)-rich ‘barrier’ that acts to restrict cyst growth but,
paradoxically, may prevent successful drug interactions
with the parasite [2].
In diseases characterised by fibrosis there is excessive
scarring which is caused by production, deposition and
cellular contraction of ECM [3]. This occurs when the
normal wound healing response, which after injury is
initiated to synthesise new connective tissue, fails to
terminate [3]. This process results in proliferation and
migration of mesenchymal fibroblasts to the area of
injury where they synthesise elevated levels of matrix
proteins such as collagen and fibronectin [3]. In liver
fibrosis the mesenchymal cells are the hepatic stellate
cells (HSC) (formally called Ito cells) which store vita-
min A located in the space of Disse within the liver
sinusoid [4]. For the liver to function normally, solutes
and growth factors in the blood plasma can enter this
space by passing through fenestrae in liver endothelial
cells (LSECs) where they come into contact with hepa-
tocytes. Upon activation, HSCs undergo a process of
trans-differentiation from a vitamin A-storing cell to a
myofibroblast phenotype [5]. A scar-like matrix is pro-
duced by the myofibroblasts that impedes the flow of
solutes to the hepatocytes and, as a result of accumu-
lating ECM products, the LSECS undergo defenestra-
tion and the hepatocytes lose there microvilli thereby
stopping the liver functioning effectively [4]. The pro-
cess of trans-differentiation of the HSC is summarised
in Figure 1.
The process of fibrogensis in the liver has been well
defined over recent years with HSC activation central
to this. The first phrase of fibrosis is initiation in
which insult to the liver results in activation of the
HSCs into myofibroblasts [5]. There are many known
types of liver insult ranging from viral infection (due
to hepatitis B, C and D), autoimmunity (primary biliary
cirrhosis, autoimmune hepatitis), inherited diseases
(cystic fibrosis, hereditary haemachromotosis), dietary
(non-alcoholic fatty liver disease) or chemical (alcohol)
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causes, and parasitic infection, the details of which are
beyond the scope of this article but have been sum-
marised by Wallace et al [6]. After the first initiation
of fibrogenesis whereby the HSCs proliferate, become
contractable, produce fibrogenic ECM components,
alter matrix degradation, recruit new myofibroblasts
and become involved in inflammatory signalling [5].
All these responses are tightly controlled by cytokine
production both from the HSCs themselves as well as
neighbouring cells.
Figure 1 Summary of the process of hepatic stellate cell (HSC) trans-differentiation. The imaged cells are LX-2 cells taken after 72hrs
growth with adipogenic factor induced quiescence on the left and activated cells on the right. The quiescent HSC phenotypically has a small
cell body with cellular processes extending into the growth area around the cell. Lipid droplets are observed in the cells that are characterised
by a lack of aSMA stress fibres, low expression of fibrosis associated genes (Col1A1, CTGF and aSMA) and increased expression of PPAR-g. Upon
activation, the cells lose their ability to store lipid droplets and have a large flat appearance. aSMA stress fibres are observed in the cells and
gene expression of fibrosis associated genes are increased while PPAR-g expression is reduced.
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Myofibroblasts are regarded by many as the cell with a
central role in liver fibrogenesis and as the main cellular
source of ECM components in liver fibrogenesis [7].
There is still some argument regarding the precise origin
of these cells but many agree that during fibrosis they
can originate from different sources. They can derive
from quiescent HSCs which are located within the centri-
lobular and perisinusoidal regions of the liver lobule but
also from portal track fibroblasts within the periportal
regions of the lobule [6]. These sub-populations of myofi-
broblasts have been demonstrated by differential staining
of myofibroblast markers [8]. Myofibroblasts have been
demonstrated to be additionally derived from epithelial-
mesenchymal transition [9] and from circulating
fibroblasts called fibrocytes [10].
It is widely accepted that kupffer cells have a role in
liver fibrogenesis. In liver fibrosis the number of macro-
phages increase and they are found to be located around
areas of tissue damage and fibrosis [6]. Alternately acti-
vated macrophages produce proline and arginase-1
which contribute to collagen synthesis [11]. Additional
evidence supporting the role of kupffer cells in fibrogen-
sis has been demonstrated in studies using the in vivo
CCL4 model of fibrosis in mice which showed that inhi-
biting kupffer cell function with gadolinium chloride
[12] resulted in reduced fibrosis.
Granuloma formation in schistosomiasis has been
described as a two stage process with a pre-granuloma-
tous stage, characterised by disorganised aggregation of
cells, and a granulomatous stage in which they become
organised [13]. The process is tightly controlled by the
host immune response. Early in the acute phase of
infection, the Th1 response is predominant in patients
and is characterised by high levels of INF-g and TNF-a,
and is associated with large granulomas around the eggs
in the liver [14]. The release of eggs gradually causes a
switch to a Th2 response that is characterised by high
levels of IL-4, IL-13 and IL-10 [14]. IL-4 and IL-13 have
been demonstrated to be important in the induction of
the Th2 response in schistosomiasis [11]. It is believed
that this switch in response is important in terms of dis-
ease severity as IL-4-/- knock-out mice die due to sepsis
as haemorrhagic lesions in the gut mucosa increase
exposure of the host to bacteria and bacterial toxins
from the gut [11,15]. It has been demonstrated that the
eggs themselves can stimulate the Th2 response with an
IL-4 inducing factor (IPSE) being produced by the egg
that stimulates activation of basophills and the expres-
sion of IL-4 and IL-13 [16]. Omega-1 has also been
identified as a major component found in soluble egg
antigen (SEA) that can condition dendritic cells for Th2
polarisation [17].
In the chronic form of schistosomiasis, the immune
response is generally down-regulated but failure to do
so in some individuals leads to development of hepatos-
plenic disease [11]. Different models of down-regulation
have been suggested. B-cells have been implicated in
this process [11]. Mice deficient in B cells fail to
undergo Th2 down-regulation and, as a result, develop a
more severe pathology with failure to decrease granu-
loma size during chronic infection [18]. Another role in
down-regulation has been demonstrated by the IL-13
receptor a2 (IL-13r a2) which has been observed to
down-modulate granulomatous inflammation and pro-
long host survival in mice [19]. Its expression is higher
both in mice and human patients with schistosomiasis
suggesting it does have an important role in disease pro-
gression [19].
Fibrosis is the most serious pathology associated with
schistosomiasis but little is known of its initiation. The
type of fibrosis observed in schistosomiasis is periportal
fibrosis, also known as Symmer’s pipe-stem fibrosis,
named after W. Symmers who first described the fibro-
sis in the liver of a patient chronically infected with S.
mansoni [20]. Four stages have been suggested in the
process of fibrosis in schistosomiasis. These are: recruit-
ment of fibroblasts and/or differentiation of HSC; prolif-
eration of the HSC; secretion of ECM molecules; and
ECM remodelling [21]. In chronic schistosomiasis, the
rate of collagen accumulation decreases and a change in
the type of collagen accumulated can occur from type
1 to type 3 as demonstrated in mice infected with
S. japonicum [22]. In progressive fibrosis the main type
of collagen produced is type 1 [23].
The development of fibrosis appears to depend on the
interaction of many different factors although an
immune response polarised towards a Th2 response is
recognised as being associated with schistosome-induced
fibrogenesis [11,15,24,25]. Indeed, high levels of IL-5
and IL-13 have been observed in patients with more ser-
ious fibrosis [24]. IL-13 has, additionally, been demon-
strated to be pro-fibrogenic in mice [15] and to be
associated with stimulation of collagens 1, 3 and 5 [11].
IL-13 has been shown to promote collagen production
in a human HSC cell line [26]. In contrast, cytokines
(TNF-a, IL-12, INF-g) and NO, associated with the Th1
response, have been observed to inhibit fibrosis in schis-
tosomiasis [11].
Different populations of myofibroblasts have been
observed to be involved in the development of fibrosis
in the granuloma with inward collagenic growth being
associated with myofibroblasts from the portal track
while outward growth is attributed to myofibroblasts
originating from HSC differentiation [13]. Macrophages
have been demonstrated to have an important role in
the development of fibrosis in schistosomiasis. The Th1
cytokines, INF-g and TNF-a can classically activate
macrophages to produce NOS-2 which in mice is
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associated with smaller granulomas and less fibrosis
[11]. In contrast, macrophages stimulated by Th2 cyto-
kines, especially IL-13, become alternatively activated
and produce arginase-1 (arg-1) and proline, higher levels
of which are associated with larger granulomas and
increased fibrosis [11]. Other factors associated with the
development of fibrosis in schistosomiasis are repeated
exposure [25] and intensity of infection [27]. In a study
on human patients, an increase in egg deposition in
chronically infected individuals was observed to shift the
immune response from a Th0 to a Th2 response and
this correlated with increased levels of IL-10 [27].
Another study on S. mansoni-infected baboons demon-
strated that repeated infection and treatment primed
lymphocytes to produce increased levels of TGF-b and
IL-4 which are known pro-fibrogenic cytokines [25].
Evidence for a role for HSC in parasitic disease
Little is known about the role of the HSC in schisto-
some-induced fibrosis, although it is thought that this
cell is one of the main sources of collagen deposition
and it plays a role in extracellular matrix remodelling
in schistosomiasis [28]. HSC have been identified in
the periphery of egg granulomas in murine and human
S. japonicum infection where myofibroblasts were
shown to be present in fibrotic patients with end-stage
disease [29]. In the mouse study, the presence of HSC
was shown using immunohistochemical techniques.
Staining for markers such as desmin and aSMA
occurred at the edges of granulomas with HSC
activation detectable after 6 weeks post-S. japonicum
infection, coinciding with the TH2 shift and down-mod-
ulation of granuloma size [29]. Peak activation of HSC
was observed in mice between 8-10 weeks post-infec-
tion, measured by aSMA expression [29]. A further
study of the S. japonicum model again demonstrated
staining for aSMA positive cells in the fibrotic area of
granulomas [30]. Staining in this model coincided with
the up-regulation of genes associated with hepatic fibro-
sis and HSC activation as well as chemokines associated
with HSC recruitment [30]. In a separate study the pre-
sence of activated HSC in human S. mansoni infection
was demonstrated [31].
Increased levels of somatostatin, which can inhibit
HSC activation, in patients infected with S.mansoni has
been shown to be associated with reduced fibrosis [32].
In rabbits infected with S. japonicum, HSC activation
was found to be characteristic of the resulting fibrosis
and could be inhibited by administration of prostaglan-
din E1 which inhibits HSC activation [33]. Leptin, and
its receptor, is found to be expressed in granulomas of
S.mansoni-infected mice [13]. Leptin is expressed in
activated HSC and increases the cells ability to produce
collagen type 1 by enhancing the effect of the TGF-b
type 2 receptor [34]. It is noteworthy that leptin defi-
ciency decreases fibrosis in S.mansoni infection in mice
further indicating a role for HSC in the development of
fibrosis [35]. Additional evidence for the involvement of
the HSC is supported in a murine study in which the
Chinese traditional medicine, heluoshugan, was observed
to decrease collagen production by inhibiting their acti-
vation [36]. Paeoniflorin, which has anti-inflammatory,
anti-allergic, and immunoregulatory effects and is com-
monly used in Chinese herbal prescriptions to treat
hepatic disorders, has been demonstrated by Li et al.
[37] to reduce fibrosis in murine S. japonicum infection
as well as inhibit collagen synthesis in IL-13-stimulated
HSC. Previously this group had demonstrated that
mouse peritoneal macrophages stimulated by SEA from
S. japonicum produced TGF-b that was able to stimulate
collagen production in HSC [37]
Vuitton’s group [38,39] postulated a possible role for
HSC in alveolar echinococcosis. Using various imaging
techniques they demonstrated that myofibroblasts were
the main cell type in areas of developing liver fibrosis;
in some regions of the liver the parenchyma was
replaced with parasitic lesions, acellular necrosis and
fibrosis and that in these areas HSC were the only cellu-
lar remnants present. Additionally, TGF-b is secreted
into the granuloma area around E. multilocularis [40]
which is a well studied model of HSC activation. Acti-
vated HSC have, additionally, been identified in Meso-
cestoides vogae cestode infection in mice with these cells
forming a cellular layer in proximity to the larval surface
and that in progressive infection the population of
SMA-positive myofibroblasts increased in fibrous lesions
around the larvae [41].
The HSC as a fibrogenesis model
The HSC has been widely used as an in vitro model of
fibrogenesis [6]. This has allowed the process of trans-
differentiation to be studied in this cell as under
normal cell culture conditions quiescent HSC sponta-
neously activate into the myofibroblast phenotype.
Primary rat HSC have been used extensively as an in
vitro model and can be obtained from rat liver tissue
by perfusion with collagenase and pronase through the
portal vein in order to obtain a suspension of non-par-
enchymal liver cells [42]. Then, due to a high fat con-
tent, HSCs can be purified using their low buoyant
density; the yield of HSCs is dependent upon rat age,
body weight and nutritional status, with older animals
fed on a normal diet or younger rats fed with a
vitamin A-supplemented diet providing the highest
number of cells [42]. Whereas much valuable informa-
tion has been obtained using rat HSCs, it is important
to undertake similar studies with human HSCs in
order to validate whether the mechanisms established
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in rodent models have relevance for human biology
[43]. Some work has been carried out using modified
rat cell isolation procedures to isolate primary human
HSCs from liver wedge sections obtained during liver
surgery [42]. Obtaining human HSCs is difficult,
however, as wedge sections do not allow adequate per-
fusion of the tissue which results in low yields of HSC
[42], and the availability of human tissue suitable for
isolation is infrequent and unpredictable [43]. Addi-
tionally, some groups report that they find human
HSC isolated cells senesce between passages 2-5 [6].
Indeed, Wallace et al. [6] noted that in their studies
only 2 cultures remained proliferative for over 5 pas-
sages, and they suggested this may be due to the fact
the cells were isolated mainly from elderly patients.
This relative lack of success has led to the develop-
ment of human HSC cell lines. The LX-2 cell line is a
recently developed human immortalised cell line, devel-
oped alongside a LX-1 cell line, which has been shown
to retain key features of HSC biology [43]. These cells
were developed by transfecting primary cells with the
pRSVTag plasmid which encodes the SV40 large T anti-
gen controlled by the rous sarcoma virus [43]. LX-1
cells were then established from the primary T antigen
culture while the LX-2 cells were established from a
sub-line of the LX-1 cells that were able to grow in
reduced serum conditions [43]. Another cell line that
has been developed is the TWNT-4 cell line immorta-
lised by retrovirally introducing human telomerase
reverse transcriptase (hTERT) into LI90 cells established
from a human liver mesenchymal tumour [42]. These
cells are considered an activated HSC type with cells
expressing platelet derived growth factor receptor-b
(PDGF-Rb), aSMA and type 1 collagen [44]. Another
cell line was developed by infecting primary HSC with a
retrovirus expressing hTERT [45]; the cells were demon-
strated to retain the features of primary HSC [45].
TGF-b has been used in numerous studies with HSC
and has been shown to promote differentiation into the
myofibroblast phenotype [3,46] and also within the
LX-2 cell line [43]. The substrate that HSC are cultured
on has, additionally, been observed to regulate their
phenotype. Primary rat HSC have been shown to have a
phenotype reverted back to a more quiescent form by
their growth on or within type 1 collagen gels compared
to cells grown on cell culture plastic [47]. Culture on
collagen gels results in cells that extend their cellular
processes into the growth area containing vitamin A,
with the cells overall forming a mesh-like structure [48].
Matrigel has been demonstrated to cause quiescence in
rat HSC and restore their vitamin A storing ability,
while culture on cell culture plastic results in activation
of the cells over time [49].
A major role of the HSC is in the storage of vitamin A
as fat droplets [42]. This has highlighted similarities with
adipocytes, the phenotype of which can be activated into
a fibroblast-type phenotype by cytokines such as PDGF,
TGFa and Leptin [50]. Reversal back into an adipocyte
has been achieved by treating the activated adipocytes
with a mixture of adipogenic factors [50]. The reversal
back into fat-storing type cells has been associated with
an increase in expression of PPARg, of which a reduced
level is observed in activated HSC [50]. This treatment
has been used on activated primary rat HSC and has
been shown to cause a decrease in collagen synthesis, an
increase in PPARg expression and restoration of the
adipogenic phenotype of quiescent HSC [50,51]. Adipo-
genic factors have additionally, been used on LX-2 cells
and were observed to cause an increase in PPARg
expression and cause accumulation of fat droplets
demonstrated by Oil-Red O staining [52]. It was further
demonstrated that use of a PPARg agonist, SB431542,
inhibits TGF-b activation of the cells [52].
Can parasites interact with HSC directly
Until recently, there were no studies that had investi-
gated the direct effects of schistosome egg antigens on
the trans-differentiation status of HSC. Anthony et al.
[53] used the LX-2 line as a model for co-culture
experiments with viable S. mansoni eggs. Not only were
the eggs able to directly affect the trans-differentiation
process of the cells but, surprisingly, they caused
regression of the LX-2 cell line into quiescent vitamin
A-storing cells characterised by increased expression of
PPAR-g. This finding may help clarify the progression
of fibrosis in schistosomiasis as this was the first report
of a direct interaction between a parasite and HSC. It is
noteworthy that the anti-diabetic thiazolidinedione drug
rosiglitazone reduces hepatic fibrosis in murine schisto-
somiasis and works by activating the PPAR-g ligand
[54]. In the studies identifying the HSC as key in granu-
loma formation [29,31], it was noted that these cells
where observed at the periphery of the granuloma and
not in the immediate vicinity of the eggs. Additionally,
it is not until the egg has been destroyed that fibrosis
is observed throughout the granuloma area. It may be
that the eggs themselves cause this down-regulation of
activation status and HSC can only be activated at
the periphery of the granuloma from a descending
concentration gradient of egg antigen or in the absence
of eggs from the granuloma after their destruction. It
may be that other parasitic diseases such as echinococ-
cosis, in which liver fibrosis is a factor, may be able to
interact with HSC where the ability to inhibit fibrogen-
esis may favour establishment of the parasite in the
mammalian host.
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Conclusions and the future
There is growing evidence that the HSC may be criti-
cally important in the progression of parasite-induced
diseases, and that the interaction of parasites or parasite
antigens with this cell can provide new insights in our
understanding of the pathogenesis of schistosomiasis
and alveolar echinoccocosis. To investigate this further,
both in vivo and in vitro approaches are possible. For
example, immunohistochemisty could be used to look at
the presence of HSC in experimental infections which
could then be correlated with the host immune
response. This approach would allow identification of
the response(s) associated with HSC activation and
severe pathology that may reveal mechanisms for
designing possible immunotherapeutic strategies includ-
ing pathology-limiting vaccines. The HSC provides an
unique in vitro model of liver fibrogenesis that has been
extensively utilised in studies of many liver diseases
[55-57]. Use of the cell in an in vitro setting has been
made easier with the availability of new cells lines of
human origin. However, this model has generally been
overlooked in relation to the study of parasite-induced
fibrogenesis. Investigating the response of the cells to
parasite antigens using techniques such as microarrays,
RNAi and flow cytometry could reveal new insights into
the process of parasite-induced fibrogenesis.
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